ReviewArrhythmia & electrophysiology review2020
Management of Cardiac Sarcoidosis in 2020.
Review in Arrhythmia & electrophysiology review, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Atrial Arrhythmias in Cardiac Sarcoidosis-Case Presentation and Systematic Review.Pacing and clinical electrophysiology : PACE · 2025Pooled it
- Prognostic role of late gadolinium-enhanced MRI in confirmed and suspected cardiac sarcoidosis: meta-analysis.The international journal of cardiovascular imaging · 2024Pooled it
- Heart transplantation in end-stage heart failure secondary to cardiac sarcoidosis: an updated systematic review.Heart failure reviews · 2023Pooled it
- Diagnosis and Management of Patients with Cardiac Sarcoidosis by a Regional Specialist Service.Diseases (Basel, Switzerland) · 2026Article
- Comparative effectiveness of disease-modifying antirheumatic drugs for patients with cardiac sarcoidosis.Rheumatology (Oxford, England) · 2025Article
- Article
- A Rare Coexistence of Klippel-Trenaunay Syndrome and Cardiac Sarcoidosis.Biomedicines · 2025Article
- Article
- 30-Year Trends in the Incidence, Characteristics, and Outcome of Cardiac Sarcoidosis in a Nationwide Cohort.JACC. Advances · 2024Article
- Review
- Cardiac Sarcoidosis: A Comprehensive Clinical Review.Reviews in cardiovascular medicine · 2024Review
- A case of myocarditis and associated atrioventricular heart block: a diagnostic conundrum.The British journal of cardiology · 2024Article
- Cardiac sarcoidosis: diagnosis and management.Frontiers in cardiovascular medicine · 2024Review
- Eyes and the heart: what a clinician should know.Heart (British Cardiac Society) · 2023Review
- Impact of respiratory gating and ECG gating onJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Combined FDG PET/MRI versus Standard-of-Care Imaging in the Evaluation of Cardiac Sarcoidosis.Radiology. Cardiothoracic imaging · 2023Article
- Real-Life Utilization of Criteria Guidelines for Diagnosis of Cardiac Sarcoidosis (CS).Journal of clinical medicine · 2023Article
- Article
- Article
- Positron Emission Tomography in Heart Failure: From Pathophysiology to Clinical Application.Journal of cardiovascular development and disease · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoidosis is an inflammatory granulomatous disease that can affect any organ. Up to one-quarter of patients with systemic sarcoidosis may have evidence of cardiac involvement. The clinical manifestations of cardiac sarcoidosis (CS) include heart block, atrial arrhythmias, ventricular arrhythmias and heart failure. The diagnosis of CS can be challenging given the patchy infiltration of the myocardium but, with the increased availability of advanced cardiac imaging, more cases of CS are being identified. Immunosuppression with corticosteroids remains the standard therapy for the acute inflammatory phase of CS, but there is an evolving role of steroid-sparing agents. In this article, the authors provide an update on the diagnosis of CS, including the role of imaging; review the clinical manifestations of CS, namely heart block, atrial and ventricular arrhythmias and heart failure; discuss updated management strategies, including immunosuppression, electrophysiological and heart failure therapies; and identify the current gaps in knowledge and future directions for cardiac sarcoidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.